Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors

This study is evaluating a new imaging scan using a radioactive probe (called 68Ga-DOTA-mPNE) to detect a protein called CD73, which may help doctors better diagnose and distinguish between different types of tumors using PET/CT imaging. **You may be eligible if...** - You are 18 or older with an expected survival of at least 12 weeks - You have not yet received radiation or chemotherapy - You are scheduled for surgery or a biopsy to confirm your diagnosis - You have at least one measurable tumor visible on imaging - You are willing to comply with follow-up requirements **You may NOT be eligible if...** - You have severe liver or kidney problems - You are pregnant, breastfeeding, or planning to conceive during the study - You are unable to lie flat for 30 minutes - You have claustrophobia or a psychiatric condition that prevents you from completing the scan Talk to your doctor to see if this trial is right for you.